Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2013

View Archived Issues

Phase II clinical trial data presented for new monoclonal antibody for type 1 diabetes

Novel nonhuman primate model developed for HCV infection

Synergistic effects on cognition seen with ZSET-1446 and galantamine, rivastigmine and memantine

Agios Pharmaceuticals patents new IDH1 inhibitors for cancer

Chinese group synthesizes novel agents for cancer

Spinifex Pharmaceuticals designs novel angiotensin AT2 receptor antagonists

Scientists at Merck Patent divulge new GCN2 inhibitors

EnVivo Pharmaceuticals synthesizes new gamma-secretase modulators

T-VEC shows potential as a treatment option for melanoma patients in phase III trials

Biocon launches ALZUMAb in India

DengueCide receives FDA orphan drug designation

TherapeuticsMD begins phase I study of its vaginal estradiol suppository

University of Alberta collaborates with BGI Shenzhen on cancer screening technology

Shionogi profiles achievements of first quarter of fiscal 2013

Phase III Allovectin trial does not meet efficacy endpoints

Advanomics receives second grant for Adva-27a

Cardium Therapeutics reports on Excellagen potential in birth defects

Galectin Therapeutics' GR-MD-02 receives FDA fast track designation

Celldex Therapeutics expands phase II ReACT study in recurrent glioblastoma

Immunomedics advances solid tumor ADC programs to phase II

Tekmira Pharmaceuticals begins phase I/II TKM-PLK1 trial

First human implantation of map3 cellular allogeneic bone graft completed

Avanir Pharmaceuticals and Merck enter co-promotion agreement for Januvia

Maxygen's shareholders approve dissolution of the company

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...